231 related articles for article (PubMed ID: 12168943)
1. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
Syrigos KN; Sitara D; Georgiou E; Harrington KJ
Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
[TBL] [Abstract][Full Text] [Related]
2. The use of chemotherapy in the management of neuroendocrine tumors.
Oberg K
Endocrinol Metab Clin North Am; 1993 Dec; 22(4):941-52. PubMed ID: 8125079
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
Ganetsky A; Bhatt V
Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
[TBL] [Abstract][Full Text] [Related]
5. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
6. Endocrine tumors of the gastrointestinal tract: systemic treatment.
Oberg K
Anticancer Drugs; 1994 Oct; 5(5):503-19. PubMed ID: 7858282
[TBL] [Abstract][Full Text] [Related]
7. Gut neuroendocrine tumors.
Hammond PJ; Bloom SR
Curr Ther Endocrinol Metab; 1994; 5():570-5. PubMed ID: 7704795
[No Abstract] [Full Text] [Related]
8. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
10. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors.
Fazio N; Oberg K
J Clin Oncol; 2004 Feb; 22(3):573-4; author reply 574-5. PubMed ID: 14752088
[No Abstract] [Full Text] [Related]
12. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.
Nguyen C; Faraggi M; Giraudet AL; de Labriolle-Vaylet C; Aparicio T; Rouzet F; Mignon M; Askienazy S; Sobhani I
J Nucl Med; 2004 Oct; 45(10):1660-8. PubMed ID: 15471830
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
14. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
15. [Treatment strategy of neuroendocrine tumors].
Ducreux M; Baudin E; Schlumberger M
Rev Prat; 2002 Feb; 52(3):290-6. PubMed ID: 11925720
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of digestive neuroendocrine tumors].
Rougier P; Toma C; Fabri MC; Ducreux M
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):117-20. PubMed ID: 7618833
[No Abstract] [Full Text] [Related]
17. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
Yalcin S
Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
[TBL] [Abstract][Full Text] [Related]
18. Current medical treatment of pancreatic neuroendocrine tumors.
Yalcin S; Oyan B; Bayraktar Y
Hepatogastroenterology; 2007; 54(73):278-84. PubMed ID: 17419276
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy of advanced digestive neuroendocrine tumours.
Rougier P; Ducreux M
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S202-6. PubMed ID: 10604131
[TBL] [Abstract][Full Text] [Related]
20. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
